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Abstract
Background: Aspirin (ASA) is a drug that can cause gastrointestinal lesions and symptoms. Colorectal cancer (CRC) is the
most prevalent type of cancer in Western countries. We assessed the effect of aspirin on the diagnostic accuracy of the faecal
immunochemical test (FIT) for CRC and/or advanced neoplasia (AN) in patients undergoing colonoscopy for gastrointestinal
symptoms.
Methods: We conducted a prospective multicentre observational study of diagnostic tests that included patients with
gastrointestinal symptoms undergoing colonoscopy between March 2012 and 2014 (the COLONPREDICT study). Symptoms
were assessed and a FIT and blood tests assessing haemoglobin and carcinoembryonic antigen (CEA) levels were
performed.
Results: The study included 3052 patients: A total of 2567 did not take aspirin (non-user group) and 485 (16%) took aspirin
(user group). Continuous treatment with ASA did not change the AUC (0.88, 0.82; p¼ 0.06), sensitivity (92%, 88%; p¼ 0.5) or
specificity (71%, 67%; p¼ 0.2) of the FIT for CRC detection. Similarly, we found no differences in the AUC (0.81, 0.79; p¼ 0.6),
sensitivity (74%, 75.5%; p¼ 0.3) or specificity (76%, 73.6%; p¼ 0.3) for AN detection. Patients with an aspirin use
of 300 mg/day had a lower prevalence of AN and the sensitivity, specificity and AUC for AN for these patients were
54%, 68% and 0.66, significantly lower than for the non-user group (p¼ 0.03).
Conclusions: Aspirin does not modify the diagnostic accuracy of FIT for CRC and/or AN in patients with gastrointestinal
symptoms. Aspirin use of 300 mg/day decreases the accuracy of the test.
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Introduction
Colorectal cancer (CRC) is the most prevalent type of
cancer in Western countries, and screening for this type
of cancer has led to a decrease in its incidence and
associated mortality.1,2 The two most widely accepted
techniques for screening in most countries are colonos-
copy and the faecal immunochemical test (FIT).1,3
Most CRC diagnoses are made in people who seek
medical attention for symptoms that include rectal
bleeding, change in intestinal rhythm, abdominal pain
and anaemia. These symptoms are very common in the
general population, hence, various risk factors have
been used to identify individuals who are more likely
to have CRC. Recently, published studies have sug-
gested that FIT is the approach with greatest diagnostic
accuracy for CRC detection in symptomatic patients4,5
as a sole biomarker or within prediction models.
Studies conducted by our research group have found
that the combination of certain signs and symptoms,
older age, male sex and a positive FIT result are asso-
ciated with a 10 higher risk of CRC.4,5 In patients
who meet these criteria, colonoscopy must be per-
formed. It has been speculated that FIT results may
be modified by certain drugs such as aspirin. Neither
antiplatelet drugs nor oral anticoagulants affect the pre-
dictive value of the test in asymptomatic populations
taking part in screening programmes; however, we do
not know the potential effect of aspirin use on FIT in
people with gastrointestinal symptoms.6,7 Aspirin has
been shown to, on the one hand, decrease the risk of
colon polyps8 and on the other, increase the likelihood
of gastrointestinal complaints and anaemia.9
Our objective was to assess whether aspirin use
changes the diagnostic accuracy of FIT in patients
with gastrointestinal symptoms.
Patients and methods
Design
We carried out a post-hoc analysis to assess whether
aspirin use affects the diagnostic accuracy of FIT in the
derivation and validation cohorts from the
COLONPREDICT study.4,5 COLONPREDICT was
a blind, multicentre cross-sectional study of diagnostic
tests. The study sought to create and validate a CRC-
predictive index based on available biomarkers and
clinical and demographic data.
Population
The study population consisted of consecutive patients
with gastrointestinal symptoms referred for colonos-
copy from primary and secondary care. Patients were
excluded if they were younger than 18 years, pregnant,
or asymptomatic and undergoing colonoscopy for
CRC screening, had a history of colonic disease and
were undergoing surveillance colonoscopy, required
hospital admission, or had symptoms that had ceased
within three months before evaluation. The trial proto-
col was approved by the Clinical Research Ethics
Committee of Galicia (Code 2011/038). Patients pro-
vided written informed consent before inclusion.
Laboratory testing
Patients were administered by nurses specifically
trained in the assessment of gastrointestinal symptoms
or doctors a questionnaire that included questions
related to medication use. In addition, all patients
underwent a blood test that included measurement of
haemoglobin and carcinoembryonic antigen (CEA)
levels, a FIT and colonoscopy.
All individuals collected a stool sample the week
before colonoscopy from one bowel movement without
specific diet or medication restrictions. They were spe-
cifically instructed to sample a stool with no visible
blood. FIT was performed using the automated
OCsensorTM (Eiken Chemical Co, Tokyo, Japan).
Samples were processed as previously described4 at
each regional reference hospital. Patients with 20 mg
of haemoglobin per gram of faeces were classified as
positive. Moreover, we measured serum haemoglobin
levels and mean corpuscular volume with a Beckman
Coulter Autoanalyzer (Beckman Coulter Inc, CA,
USA) and serum CEA levels using a chemiluminescent
microparticle immunoassay (UniCel DXI 800;
Beckman Coulter, CA, USA).
Definition of cohorts
Patients were divided into two groups: users and non-
users. We defined the ‘users’ as those reporting chronic
use of aspirin. Chronic use was defined as patients
taking aspirin for more than one year at least five
days a week. ‘Non-users’ were individuals who did
not report chronic use of aspirin. Patients who reported
a sporadic intake of aspirin were excluded. The dose
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and duration of aspirin use were verified during the
patient’s interview with the physician or nurse when
the medical history was reviewed. At some participating
centres, dosage and duration of aspirin use were also
verified by inspecting their electronic prescription rec-
ords and the number of pack of pills withdrawn from
the pharmacy. It was recommended that patients not
suspend aspirin use before FIT or prior to colonoscopy.
Colonoscopy
All colonoscopies were performed by experienced
endoscopists (each performing >200 colonoscopies
per year). Colonoscopy was performed blind to the
questionnaire and other test results. Before colonos-
copy, endoscopists performed a digital rectal examin-
ation and an anuscopy. Colonoscopy quality was
ensured by following the Spanish Gastroenterological
Association and Spanish Society for Digestive
Endoscopy guidelines.10 We considered colonoscopy
complete if cecal intubation is achieved or a complete
neoplastic stenosis is found.
Outcomes
The main outcome was the diagnosis of CRC and
advanced neoplasia (AN). Adenomas 10mm in size,
with villous architecture, high-grade dysplasia or intra-
mucosal carcinoma were classified as advanced aden-
omas. The location of the CRC was described as
rectum, or distal or proximal to the splenic flexure.
Tumour staging was performed according to the sev-
enth edition of the American Joint Committee on
Cancer (AJCC) classification.11 AN was defined as
advanced adenoma or invasive cancer. Data from
each individual were recorded in an online database.
Statistical analysis
A descriptive analysis of the sample was performed.
Comparisons between the groups (non-users and
users) were conducted using chi-square and/or
Fisher’s exact tests for categorical variables, and the
non-parametric Mann-Whitney test for continuous
variables.
Patients were classified into three groups by level of
aspirin use: none, less than 300mg/day and 300mg/day
or more. The effect of aspirin use on the positivity of
the FIT was analysed with logistic regression, calculat-
ing odds ratios (both crude and adjusted for covariates
reflecting other factors potentially involved). To assess
the accuracy of the FIT in the diagnosis of CRC and
AN, sensitivity, specificity and areas under the receiver
operating characteristic curve (AUCs) were calculated,
together with their confidence intervals. These
estimators were compared between groups of aspirin
use with a chi-square test to compare proportions and
homogeneity of the areas.
All analyses were performed using IBM SPSS
Statistics for Windows, version 22.0 and MedCalc, ver-
sion 12.7.0.0.
Results
Description of the sample
We included 3116 patients, of whom 64 were subse-
quently excluded, yielding a final sample of 3052
(Figure 1). Of the 3052 participants, 2567 (84%)
reported not taking aspirin (non-user group), and 485
(16%) taking aspirin (user group). In the user group,
427 (88%) took less than 300mg/day of aspirin while 58
individuals took more 300mg/day. As expected, more
men were taking aspirin than women (p< 0.05) and
users were older than non-users (p< 0.001) (Table 1).
We detected CRC in 350 (11.4%) patients, located in
the rectum, in the distal and proximal colon respect-
ively in 28.4%, 50.7% and 20.9% of cases. The
tumour staging was: 0 in 2.8% of cases, I in 18.6%,
II in 25.1%, III in 37.7% and IV in 15.8%.
Additionally, we found advanced adenomas in 739
(24.2%) patients. Overall, we detected AN in 1089
(35.6%) patients.
Effect of aspirin use on FIT results
The FIT was positive in 36% of patients overall (1100/
3052), 38.8% (188/485) in the user group and 35.5%
(912/2567) in the non-user group (p¼ 0.2). Patients
with positive results had a higher mean age than
those with negative results (67.7 vs 63.7 years;
p< 0.0005). The FIT was positive in 23.1% (99/428)
of patients under 50 years and 37.9% (996/2624) of
3,116 patients included
3,052 patients evaluated
2,567 nonusers group
35,8% FIT positive
(912/2,567)
38,8% FIT positive
(188/485)
485 users group
64 excluded from analysis
• Not return blood/FIT: 50
• Not attended colonoscopy: 14
Figure 1. Recruitment and participant flow through the study.
FIT: faecal immunochemical test.
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those aged 50 years and above (p< 0.0005). Further,
those who had positive results tended to have a lower
haemoglobin concentration than those with negative
results (13.2 vs 13.4 g/dl, p¼ 0.06). The test was positive
in 38.9% (661/1699) patients with haematochezia and
only 32.3% (438/1353) of those who didn’t show this
sign (p< 0.0005). In the multivariate analysis (Table 2),
we found that men, individuals above 50 years of age,
with a low concentration of haemoglobin, haematoche-
zia or levels of CEA above 3mg/dl were more likely to
have a positive FIT result.
Diagnostic accuracy for CRC in users and
non-users
In the user group, there were 51 cases (10.5%) of CRC,
of whom 44 (88%) had a positive FIT result. The sen-
sitivity and specificity of the FIT for CRC in the user
group were 88% and 67%, respectively, while the AUC
was 0.82 (Figure 2). In this group, 123 (25.3%) individ-
uals were found to have advanced adenoma, 82 (67%)
of the cases being detected with the FIT. The sensitivity
and specificity of the FIT for AN, in the user group
were 75% and 73%, respectively (Table 3), while the
AUC was 0.79 (Figure 3).
In the non-user group, there were 299 (11.6%) cases
of CRC, of whom 275 (92%) had a positive FIT result.
The sensitivity and specificity of the FIT for CRC in the
non-user group were 92% and 71%, respectively, and
the AUC was 0.88 (Table 3). In this group, we detected
616 (23.9%) cases of advanced adenoma, of which 351
(56%) cases were detected with the FIT. The sensitivity
and specificity of the FIT for AN in the user group were
74% and 76%, respectively, while the AUC was 0.81.
We did not observe significant differences between the
user and non-user groups in terms of sensitivity, speci-
ficity and AUCs for AN.
Effect of aspirin dose on diagnostic accuracy
When we assessed whether the aspirin dose (more or
less than 300mg/day) modified the presence of AN, we
found a lower risk of developing AN and CRC among
those who took a dose 300mg/day (Table 4). Among
the 427 patients who took less than 300mg/day, 50
(11.7%) were found to have CRC, while we found
just one (1.7%) patient with CRC among those who
took 300mg/day or more. The mean duration of aspirin
use was higher in patients taking 300mg/day than
those using lower doses (less than 300mg/day) (56 vs
43 months, p< 0.05). We did not observe significant
differences in FIT positivity as a function of aspirin
dose: 38.8% among those taking doses 300mg/day
vs 37.9% among those taking less than 300mg/day.
For AN, the sensitivity and specificity of the FIT in
the group taking 300mg/day were 54% and 68%
compared to 77% and 74% in those taking less
(under 300mg/day), the differences not being signifi-
cant (Table 5), while the AUC was 0.79 among those
taking< 300mg/day and 0.66 among those using higher
doses ( 300mg/day) (p¼ 0.09).
Discussion
In this study, we have observed no significant difference
in the rate of positive FIT results in patients seeking
Table 1. Characteristics of individuals included in the study.
Total
(n¼ 3052)
User group
(n¼ 485)
Non-user group
(n¼ 2567) p valuea
Positive FIT result 1090 (35.7%) 188 (38.8%) 912 (35.8%) 0.2
Age (years) 67 (SD: 13) 72.5 (SD: 9) 63.7(SD: 14) <0.0005
Male sex (%) 1528 (50%) 282 (58.1%) 1246 (48.5%) <0.0005
Serum haemoglobin (mean, SD g/dl) 13.3 (2.6) 12.9 (1.9) 13.4 (2.8) <0.0005
<10 g/dl 38 (7.8%) 135 (5.2%)
10–12 g/dl 105 (21.6%) 403 (15.6%) <0.0005
>12 g/dl 342 (70.6%) 2029 (79%)
Carcinoembryonic antigen (mg/dl) 1.8 (1–3.1) 2 (1.3–3.1) 1.7 (1–2.8) <0.001
<3 mg/dl 350 (72.2%) 2014 (78.9%) 0.01
3 mg/dl 135 (27.8%) 542 (21.1%)
Results of colonoscopy
Cancer 350 (11.4%) 51 (10.5%) 299 (11.6%) 0.5
Advanced adenoma 739 (24.2%) 123 (25.3%) 616 (23.9%)
ap value Mann-Whitney U. FIT: faecal immunochemical test.
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Table 2. Factors associated with a diagnosis of advanced neoplasia in patients with a positive faecal immunochemical test result.
Univariate analysis Multivariate analysis
N þ FIT OR (95% CI) p value OR (95% CI) p value
Sex
Female 1524 481 (31.5) Reference
Male 1528 619 (40.5) 1.5 (1.3–1.7) <0.0005 1.5 (1.3–1.8) <0.0005
Aged (years)
< 50 428 99 (23.1) Reference
 50 2624 1001 (38.1) 2.0 (1.5–2.5) <0.0005 2.0 (1.5–2.6) <0.0005
Aspirin
Not 2567 912 (35.5) Reference Reference
Yes 485 188 (38.8) 1.1 (0.9–1.4) 0.2 0.9 (0.7–1.2) 0.3
< 300 mg 427 167 (38.8) 1.1 (0.9–1.4) 0.2 1.0 (0.8–1.3) 1.0
300 mg 58 22 (37.9) 1.0 (0.6–1.7) 0.9 0.5 (0.3–1.1) 0.08
Haematochezia
Not 1353 438 (32.3) Reference Reference
Yes 1699 661 (38.9) 1.3 (1.1–1.5) <0.0005 1.5 (1.3–1.8) <0.0005
Haemoglobin
>12 g/dl 2371 790 (33.3) Reference Reference
10–12 g/dl 508 224 (44) 1.5 (1.2–1.9) <0.0005 1.7 (1.4–2.2) 0.0005
<10 g/dl 173 86 (49.7) 1.9 (1.4–2.7) <0.0005 1.9 (1.3–2.8) 0.0005
Carcinoembryonic antigen
< 3 mg /dl 2364 765 (32.3) Reference Reference
 3 mg/dl 677 334 (48.6) 1.9 (1.6–2.3) <0.0005 1.6 (1.3–2.0) <0.0005
FIT: faecal immunochemical test; OR: odds ratio; CI: confidence interval.
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Figure 2. Receiver operating characteristic curve analysis for
colorectal cancer diagnosis with faecal immunochemical test as a
function of aspirin use.
ASA: acetylsalicylic acid; CI: confidence interval.
Table 3. Sensitivity, specificity and area under the receiver oper-
ating characteristic curve (AUC) for colorectal cancer and advanced
neoplasia as a function of aspirin use.
Advanced neoplasia
Non-users Users Significancea
Sensitivityb 74 (70–77) 75 (66–82) 0.9
Specificityb 76 (74–78) 73 (68–78) 0.28
AUC2 0.81 (0.78–0.82) 0.79 (0.74–0.83) 0.6
Colorectal cancer
non-users Users Significancea
Sensitivityb 92 (88–95) 88.00 (75–95) 0.5
Specificityb 71 (69–73) 66.97 (62–71) 0.19
AUCb 0.88 (0.86–0.90) 0.82 (0.77–0.88) 0.06
aDifferences with p< 0.05 are considered statistically significant.
bValues are expressed as percentage and 95% confidence interval.
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medical attention for digestive symptoms as a function
of whether they reported aspirin use. The sensitivity of
the FIT was similar in the two groups (75% users vs
74% non-users).
Levi et al.12 in a retrospective study with fewer
aspirin users (980 non-users and 170 users) also found
no differences in sensitivity or specificity of the FIT in
symptomatic patients. In that study, the sensitivity, spe-
cificity and positive predictive value (PPV) of the FIT
for AN in aspirin users were 66%, 92% and 52%,
respectively, while these values were 46%, 93% and
38%, respectively, in the control group. Our findings
differ from these results in that we found sensitivity,
specificity and PPV in the non-user group of 74, 76%
and 50%, respectively. Levi et al. do not provide infor-
mation about the positivity of the test. The differences
observed in the test sensitivity may be due to the dif-
ferences in prevalence of the lesions detected and the
design of the study (retrospective vs prospective). In
contrast to our study, the prevalence of AN in the
study by Levi et al.12 was very low (9.3%), comparable
to values of 1.3% to 10.7% found in asymptomatic
individuals in prospective studies.13,14 Research based
on asymptomatic individuals, such as the
COLONPREV study,14 has also failed to find differ-
ences in the predictive value of the test between aspirin
users and non-users. Analysing the predictive value as a
function of aspirin use, we found that the predictive
value of the FIT was lower for those taking the highest
doses of the drug. Further, the prevalence of AN was
lower in patients on higher doses of aspirin (>300mg/
day). It is known that aspirin reduces the occurrence of
adenomas8,15 and that a lower prevalence of lesions
decreases the predictive value of diagnostic tests. With
regards to the most suitable dose of aspirin to reduce
the occurrence of adenomas, there is no consensus
between studies15,16 and this may be due to the
number of patients included, the type of patients (mod-
erate vs high risk) or the duration of aspirin use.
The prevalence of AN in our study was high (35.6%).
Blumenstein et al.17 observed in a prospective study that
the prevalence of CRC in individuals of at least 55 years
of age was equivalent in symptomatic individuals
(1.21%) and the control group (1.02%); advanced aden-
omas were observed in significantly fewer symptomatic
patients (5.67%) than matched asymptomatic controls
(8.03%); and finally, polyps were found significantly less
often in symptomatic patients (25.0%) than in matched
controls (33.6%). However, in another study,18 the
prevalence was somewhat higher, with colonic neoplasia
and CRC being identified in 17.3% and 11.3% cases,
respectively of a total 1013 symptomatic individuals
(mean age 59.9 years, 52.3% females) from a multi-
ethnic Asian background. The high prevalence we
found could be attributable to the inclusion of patients
referred for in-hospital high-resolution consultation for
colon cancer.
Table 4. Prevalence of advanced adenoma and cancer as a function of aspirin dose.
Individuals AA no. (%) p value CRC No. (%) p value
Non-user group 2567 616 (24%) 299 (11.6%)
User group
Aspirin< 300 mg
per day
427 111 (25.9%) 0.9 50 (11.7%) 0.07
Aspirin 300 mg
per day
58 12 (20.6%) 1 (1.7%)
AA: advanced adenoma; CRC: colorectal cancer
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Figure 3. Receiver operating characteristic curve analysis for
advanced neoplasia diagnosis with faecal immunochemical test as
a function of aspirin use.
ASA: acetylsalicylic acid; CI: confidence interval.
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The prevalence of aspirin use in the general popu-
lation is very high. Low-dose aspirin use is indicated
for primary prevention of cardiovascular events.
Aspirin is taken by about 17% of asymptomatic indi-
viduals aged over 65 years19 and 25% of patients
admitted to hospital for gastrointestinal bleeding.
This drug is known to cause lesions in the stomach
and duodenum, and can lead to an increase in the
bleeding of colon lesions.20 In our study, 16% of
symptomatic patients took aspirin. Aspirin use
among asymptomatic people who attended screening
tests ranged between 8.9% and 12% with a mean age
between 59 and 62 years of age, respectively.6,13 As in
previous studies, we found that aspirin users were
older and more likely to be male.13
Further, aspirin may increase the onset of digestive
symptoms that can lead patients to seek medical atten-
tion. A meta-analysis of 59 studies found that 5.2% of
individuals receiving aspirin reported a minor gastro-
intestinal complaint (abdominal pain, dyspepsia, or
nausea/vomiting), vs 3.7% of placebo participants.
The corresponding summary odds ratio was 1.46,
while the odds ratios for dyspepsia and abdominal
pain were 3.17 and 1.92, respectively.9 Further, aspirin
enhances the onset of anaemia and gastrointestinal
bleeding.21 In our study, we found that aspirin users
had lower levels of haemoglobin, and this may be
related to the harmful effect of this drug on the gastro-
intestinal mucosa, since the prevalence of AN was simi-
lar in both groups. Despite the potential adverse effects
of aspirin, treatment cessation may increase the likeli-
hood of cardiovascular complications (primarily, cere-
bral stroke and ischaemic heart disease).
The present study is strengthened by a number of
observations. First, it is a post-hoc analysis within a
prospective clinical trial in symptomatic patients with-
out selection bias, which should minimise confounders
for the detection of advanced adenomas and AN.
Second, the number of cases analysed is higher than
that reported to date with a high prevalence of CRC.
Third, this is the largest study that assesses the effect of
a treatment with aspirin in terms of diagnostic accuracy
for CRC and AN.
The study also has some limitations. First, we do not
know to what extent patients who were taking aspirin
may show a positive FIT result due to lesions in the
stomach and small intestine. Additionally, we were not
able to determine whether the clinical signs that
prompted patients to seek medical attention were
related to aspirin intake.
In summary, aspirin use did not change the diagnos-
tic accuracy of FIT in patients with gastrointestinal
symptoms. For this reason, we do not recommend dis-
continuation of aspirin treatment in patients who seek
medical addition for symptoms suggestive of CRC.
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